Original Article

You have full text access to this OnlineOpen article

Prognosis of chronic hepatitis c: Results of a large, prospective cohort study†

  1. Claus Niederau M.D.1,*,
  2. Stefan Lange2,
  3. Tobias Heintges1,
  4. Andreas Erhardt1,
  5. Marlies Buschkamp1,
  6. Dietmar Hürter1,
  7. Marek Nawrocki1,
  8. Lothar Kruska3,
  9. Frank Hensel1,
  10. Wolfgang Petry1,
  11. Dieter Häussinger1

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510280632

Issue

Hepatology

Hepatology

Volume 28, Issue 6, pages 1687–1695, December 1998

Additional Information

How to Cite

Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hürter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W. and Häussinger, D. (1998), Prognosis of chronic hepatitis c: Results of a large, prospective cohort study. Hepatology, 28: 1687–1695. doi: 10.1002/hep.510280632

Author Information

  1. 1

    Department of Medicine, Division of Gastroenterology, Hepatology, and Infectious Diseases, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

  2. 2

    Department of Medical Informatics, Biometrics and Epidemiology, Ruhr-Universität Bochum, Bochum, Germany

  3. 3

    Dr. Stein-Laboratory, Mönchengladbach, Germany

*Department of Internal Medicine, St. Josef-Hospital, Academic Teaching Hospital, Mülheimer Str. 83, 46045 Oberhausen, Germany. Fax: 49-208-837309

  1. †

    Dedicated to Prof. Dr. Georg Strohmeyer on the occasion of his 70th birthday.

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 3 AUG 1998
  4. Manuscript Received: 10 MAR 1998

Funded by

  • Van-Meeteren-Foundation and the Gottfried-Wilhelm-Leibniz Prize

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (110K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Soji Shimomura, Shuhei Nishiguchi, Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection, Hepatology Research, 2012, 42, 1
    Direct Link:
  2. 2
    Necati Örmeci, Hakan Erdem, Basic answers to complicated questions for the course of chronic hepatitis C treatment, Expert Review of Gastroenterology & Hepatology, 2012, 6, 3, 371

    CrossRef

  3. 3
    Masayuki Kurosaki, Naoki Hiramatsu, Minoru Sakamoto, Yoshiyuki Suzuki, Manabu Iwasaki, Akihiro Tamori, Kentaro Matsuura, Sei Kakinuma, Fuminaka Sugauchi, Naoya Sakamoto, Mina Nakagawa, Namiki Izumi, Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C, Journal of Hepatology, 2012, 56, 3, 602

    CrossRef

  4. 4
    Emad F. Eskander, Ahmed A. Abd-Rabou, Mervat S. Mohamed, Shaymaa M. M. Yahya, Olfat G. Shaker, Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy?, Indian Journal of Clinical Biochemistry, 2012,

    CrossRef

  5. 5
    Emad F. Eskander, Ahmed A. Abd-Rabou, Shaymaa M.M. Yahya, Olfat G. Shaker, Mervat S. Mohamed, Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients?, Clinical Biochemistry, 2012, 45, 1-2, 3

    CrossRef

  6. 6
    N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, H. Kumada, Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 2
    Direct Link:
  7. 7
    Mayu Ohnishi, Masataka Tsuge, Tomohiko Kohno, Yizhou Zhang, Hiromi Abe, Hideyuki Hyogo, Yuki Kimura, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Hidenori Ochi, C. Nelson Hayes, Shinji Tanaka, Koji Arihiro, Kazuaki Chayama, IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, Journal of Gastroenterology, 2012,

    CrossRef

  8. 8
    Shiv K. Sarin, Manoj Kumar, Natural history of HCV infection, Hepatology International, 2012,

    CrossRef

  9. 9
    Yongjung Park, Yoonmi Seok, Jonghyeon Choi, Hyon-Suk Kim, Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories, Clinical Biochemistry, 2012, 45, 1-2, 175

    CrossRef

  10. 10
    Amy Matser, Anouk Urbanus, Ronald Geskus, Mirjam Kretzschmar, Maria Xiridou, Marcel Buster, Roel Coutinho, Maria Prins, The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam, Addiction, 2012, 107, 3
    Direct Link:
  11. 11
    Jorge A. Marrero, Zakim and Boyer's Hepatology, 2012,

    CrossRef

  12. 12
    Ichiro Konishi, Yoichi Hiasa, Yoshio Tokumoto, Masanori Abe, Shinya Furukawa, Kumiko Toshimitsu, Bunzo Matsuura, Morikazu Onji, Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus, Hepatology Research, 2011, 41, 10
    Direct Link:
  13. 13
    Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy, Journal of Medical Virology, 2011, 83, 6
    Direct Link:
  14. 14
    Hidenori Toyoda, Takashi Kumada, Yuji Kaneoka, Atsuyuki Maeda, Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma, Annals of Surgery, 2011, 254, 2, 326

    CrossRef

  15. 15
    Hidenori Toyoda, Takashi Kumada, Kazuhiko Hayashi, Takashi Honda, Yoshiaki Katano, Hidemi Goto, Takahisa Kawaguchi, Yoshiki Murakami, Fumihiko Matsuda, Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene, Journal of Medical Virology, 2011, 83, 9
    Direct Link:
  16. 16
    E. Maillard, Épidémiologie, histoire naturelle et pathogenèse du carcinome hépatocellulaire, Cancer/Radiothérapie, 2011, 15, 1, 3

    CrossRef

  17. 17
    Masahiro Takita, Satoru Hagiwara, Tadaaki Arizumi, Sousuke Hayaishi, Taisuke Ueda, Satoshi Kitai, Norihisa Yada, Tatsuo Inoue, Yasunori Minami, Hobyung Chung, Kazuomi Ueshima, Toshiharu Sakurai, Masatoshi Kudo, Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy, Digestion, 2011, 84, s1, 56

    CrossRef

  18. 18
    Jae Young Jang, Raymond T. Chung, Chronic Hepatitis C, Gut and Liver, 2011, 5, 2, 117

    CrossRef

  19. 19
    Eiji Ohara, Nobuhiko Hiraga, Michio Imamura, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Tomohiko Kono, Mayu Onishi, Daizaburo Hirata, Fukiko Mitsui, Tomokazu Kawaoka, Masataka Tsuge, Shoichi Takahashi, Hiromi Abe, C. Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Shinji Tanaka, Kazuaki Chayama, Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, Journal of Hepatology, 2011, 54, 5, 872

    CrossRef

  20. 20
    Olfat G. Shaker, Emad F. Eskander, Shaymaa M.M. Yahya, Mervat S. Mohamed, Ahmed A. Abd-Rabou, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients, Clinica Chimica Acta, 2011, 412, 7-8, 593

    CrossRef

  21. 21
    Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Takahisa Kawaguchi, Yoshiki Murakami, Fumihiko Matsuda, Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C, Journal of Medical Virology, 2011, 83, 7
    Direct Link:
  22. 22
    Nobuhiko Hiraga, Hiromi Abe, Michio Imamura, Masataka Tsuge, Shoichi Takahashi, C. Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama, Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus, Hepatology, 2011, 54, 3
    Direct Link:
  23. 23
    Hiromi Abe, Michio Imamura, Nobuhiko Hiraga, Masataka Tsuge, Fukiko Mitsui, Tomokazu Kawaoka, Shoichi Takahashi, Hidenori Ochi, Toshiro Maekawa, C. Nelson Hayes, Chise Tateno, Katsutoshi Yoshizato, Shoichi Murakami, Nobuyuki Yamashita, Takashi Matsuhira, Kenji Asai, Kazuaki Chayama, ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, Journal of Hepatology, 2011, 55, 1, 11

    CrossRef

  24. 24
    Julien Vergniol, Juliette Foucher, Eric Terrebonne, Pierre–Henri Bernard, Brigitte le Bail, Wassil Merrouche, Patrice Couzigou, Victor de Ledinghen, Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C, Gastroenterology, 2011, 140, 7, 1970

    CrossRef

  25. 25
    Luca Valenti, MariaGrazia Rumi, Enrico Galmozzi, Alessio Aghemo, Benedetta Del Menico, Stella De Nicola, Paola Dongiovanni, Marco Maggioni, Anna Ludovica Fracanzani, Raffaela Rametta, Massimo Colombo, Silvia Fargion, Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C, Hepatology, 2011, 53, 3
    Direct Link:
  26. 26
    Nobuhiko Hiraga, Michio Imamura, Hiromi Abe, C. Nelson Hayes, Tomohiko Kono, Mayu Onishi, Masataka Tsuge, Shoichi Takahashi, Hidenori Ochi, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Chise Tateno, Katsutoshi Yoshizato, Hirotaka Matsui, Akinori Kanai, Toshiya Inaba, Shinji Tanaka, Kazuaki Chayama, Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo, Hepatology, 2011, 54, 3
    Direct Link:
  27. 27
    P. C. Thomson, C. Williams, C. Aitken, J. Ball, N. Wysocka, R. Brown, R. S. Rodger, A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine, NDT Plus, 2010, 4, 1, 32

    CrossRef

  28. 28
    Kazuaki Chayama, C. Nelson Hayes, Kentaro Yoshioka, Hisataka Moriwaki, Takeshi Okanoue, Shotaro Sakisaka, Tetsuo Takehara, Makoto Oketani, Joji Toyota, Namiki Izumi, Yoichi Hiasa, Akihiro Matsumoto, Hideyuki Nomura, Masataka Seike, Yoshiyuki Ueno, Hiroshi Yotsuyanagi, Hiromitsu Kumada, Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C, Hepatology Research, 2010, 40, 12
    Direct Link:
  29. 29
    Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Kazuaki Chayama, Yusuke Nakamura, Hiromitsu Kumada, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin, Hepatology, 2010, 52, 2
    Direct Link:
  30. 30
    Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin, Journal of Medical Virology, 2010, 82, 4
    Direct Link:
  31. 31
    Nazish Bostan, Tariq Mahmood, An overview about hepatitis C: A devastating virus, Critical Reviews in Microbiology, 2010, 36, 2, 91

    CrossRef

  32. 32
    Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T. P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatology International, 2010, 4, 2, 439

    CrossRef

  33. 33
    Carsten Kamphues, Katharina Lotz, Christoph Röcken, Thomas Berg, Dennis Eurich, Johann Pratschke, Peter Neuhaus, Ulf P. Neumann, Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients, Clinical Transplantation, 2010, 24, 5
    Direct Link:
  34. 34
    Myoung Hee Lee, Jae Youn Cheong, Soon Ho Um, Yeon Seok Seo, Dong Joon Kim, Seong Gyu Hwang, Jin Mo Yang, Kwang-Hyub Han, Sung Won Cho, Comparison of Surrogate Serum Markers and Transient Elastography (Fibroscan) for Assessing Cirrhosis in Patients with Chronic Viral Hepatitis, Digestive Diseases and Sciences, 2010, 55, 12, 3552

    CrossRef

  35. 35
    Robert J. Wong, Robert Gish, Todd Frederick, Natalie Bzowej, Catherine Frenette, Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series, Digestive Diseases and Sciences, 2010, 56, 2, 578

    CrossRef

  36. 36
    Mazen Noureddin, Marc G Ghany, Editorial: Treatment of Patients With HCV-Related Cirrhosis With Peginterferon and Ribavirin: Swinging the Pendulum Toward Treatment, The American Journal of Gastroenterology, 2010, 105, 10, 2174

    CrossRef

  37. 37
    A.A. Pillai, V.S. Lee, E. Wang, M.E. Rinella, J. Levitsky, Factors Associated With Sustained Virological Response in Liver Transplant Recipients With Recurrent Hepatitis C, Transplantation Proceedings, 2010, 42, 9, 3647

    CrossRef

  38. 38
    M. M. G. Godoy, E. P. A. Lopes, R. O. Silva, F. Hallwass, L. C. A. Koury, I. M. Moura, S. M. C. Gonçalves, A. M. Simas, Hepatitis C virus infection diagnosis using metabonomics, Journal of Viral Hepatitis, 2010, 17, 12
    Direct Link:
  39. 39
    Morris Sherman, Hepatocellular carcinoma: New and emerging risks, Digestive and Liver Disease, 2010, 42, S215

    CrossRef

  40. 40
    Tetsuya Nishiura, Hideaki Watanabe, Koji Yano, Masahiro Ito, Seigo Abiru, Toshifumi Fujimoto, Atsumasa Komori, Hiroshi Yatsuhashi, Yojiro Matsuoka, Hiromi Ishibashi, Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, Journal of Medical Ultrasonics, 2010, 38, 1, 13

    CrossRef

  41. 41
    Wai-Kay Seto, Ching-Lung Lai, James Fung, Ivan Hung, John Yuen, John Young, Danny Ka-Ho Wong, Man-Fung Yuen, Natural history of chronic hepatitis C: Genotype 1 versus genotype 6, Journal of Hepatology, 2010, 53, 3, 444

    CrossRef

  42. 42
    T. J. S. Cross, V. Calvaruso, S. Maimone, I. Carey, T. P. Chang, M. Pleguezuelo, P. Manousou, A. Quaglia, F. Grillo, A. P. Dhillon, G. M. Dusheiko, A. K. Burroughs, P. M. Harrison, Prospective comparison of Fibroscan, King’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection, Journal of Viral Hepatitis, 2010, 17, 8
    Direct Link:
  43. 43
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  44. 44
    Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response, Journal of Medical Virology, 2009, 81, 3
    Direct Link:
  45. 45
    Kaori Morota, Ryo Fujinami, Hideki Kinukawa, Taiji Machida, Kenichi Ohno, Haruhisa Saegusa, Katsumichi Takeda, A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen, Journal of Virological Methods, 2009, 157, 1, 8

    CrossRef

  46. 46
    Yoshiaki Iwasaki, Yasushi Shiratori, Shuhei Hige, Shuhei Nishiguchi, Hitoshi Takagi, Morikazu Onji, Haruhiko Yoshida, Namiki Izumi, Yutaka Kohgo, Kyosuke Yamamoto, Nobuhiro Sato, Akitaka Shibuya, Hidetsugu Saito, Michio Sata, Kazuyuki Suzuki, Shuichi Kaneko, Mitsuhiko Moriyama, Masao Omata, A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan, Hepatology International, 2009, 3, 3, 468

    CrossRef

  47. 47
    Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus, Journal of Medical Virology, 2009, 81, 6
    Direct Link:
  48. 48
    Hitoshi Yoshiji, Ryuichi Noguchi, Mitsuteru Kitade, Kosuke Kaji, Yasuhide Ikenaka, Tadashi Namisaki, Junichi Yoshii, Koji Yanase, Masaharu Yamazaki, Tatsuhiro Tsujimoto, Takemi Akahane, Hideto Kawaratani, Masahito Uemura, Hiroshi Fukui, Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats, Journal of Gastroenterology, 2009, 44, 5, 483

    CrossRef

  49. 49
    Shirley X. Hu, Namgyal L. Kyulo, Victor W. Xia, Donald J. Hillebrand, Ke-Qin Hu, Factors Associated With Hepatic Fibrosis In Patients With Chronic Hepatitis C, Journal of Clinical Gastroenterology, 2009, 43, 8, 758

    CrossRef

  50. 50
    J. Fung, C.-L. Lai, M.-F. Yuen, Hepatitis B and C virus-related carcinogenesis, Clinical Microbiology and Infection, 2009, 15, 11
    Direct Link:
  51. 51
    Sara Raimondi, Savino Bruno, Mario U. Mondelli, Patrick Maisonneuve, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis, Journal of Hepatology, 2009, 50, 6, 1142

    CrossRef

  52. 52
    Birke Bartosch, Robert Thimme, Hubert E. Blum, Fabien Zoulim, Hepatitis C virus-induced hepatocarcinogenesis, Journal of Hepatology, 2009, 51, 4, 810

    CrossRef

  53. 53
    Matthew M Yeh, Hubert Darius-J Daniel, Michael Torbenson, Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers, Modern Pathology, 2009, 23, 2, 276

    CrossRef

  54. 54
    L. Prasad, V. M. Spicher, F. Negro, M. Rickenbach, M. Zwahlen, Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study, Journal of Viral Hepatitis, 2009, 16, 9
    Direct Link:
  55. 55
    Francesca Fioredda, Andrea Moser, Luisella Bertoluzzo, Herwig Lackner, Raffaella Giacchino, Milena LaSpina, Luisella Lazier, Caterina Riva, Mareva Giacchino, Donatella Fraschini, Eva Frey, Angela Sementa, Angela Pistorio, Riccardo Haupt, Natural course of HCV infection in childhood cancer survivors, Supportive Care in Cancer, 2009, 18, 11, 1413

    CrossRef

  56. 56
    Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, The American Journal of Medicine, 2009, 122, 5, 479

    CrossRef

  57. 57
    Quentin M. Anstee, Mark Wright, Robert Goldin, Mark R. Thursz, Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis, Clinics in Liver Disease, 2009, 13, 1, 117

    CrossRef

  58. 58
    Nami Mori, Michio Imamura, Yoshiiku Kawakami, Hiromi Saneto, Tomokazu Kawaoka, Shintaro Takaki, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama, Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy, Journal of Medical Virology, 2009, 81, 4
    Direct Link:
  59. 59
    Sam Galhenage, Manal F. Abdelmalek, The impact of steatosis and alcohol on hepatitis C, Current Hepatitis Reports, 2009, 6, 2, 39

    CrossRef

  60. 60
    H. PATEL, E. J. HEATHCOTE, When to treat and the benefits of treating hepatitis C in patients with haemophilia, Haemophilia, 2009, 15, 1
    Direct Link:
  61. 61
    Silvia Paggi, Agostino Colli, Mirella Fraquelli, Mauro Viganò, Paolo Del Poggio, Corinna Facciotto, Massimo Colombo, Guido Ronchi, Dario Conte, A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: A comparison using histology with internal–external validation, Journal of Hepatology, 2008, 49, 4, 564

    CrossRef

  62. 62
    S A McDonald, S J Hutchinson, S M Bird, C Robertson, P R Mills, J F Dillon, D J Goldberg, A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland, British Journal of Cancer, 2008, 99, 5, 805

    CrossRef

  63. 63
    Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Akihide Masumoto, Toshihiro Maruyama, Makoto Nakamuta, Munechika Enjoji, Koichi Azuma, Junya Shimono, Hironori Sakai, Shinji Shimoda, Jun Hayashi, Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group, Journal of Gastroenterology and Hepatology, 2008, 23, 7pt1
    Direct Link:
  64. 64
    Amy Lin, Jaydeep S. Kadam, Henry C. Bodenheimer, John Leonard, Maureen A. Joyce, Gerond Lake-Bakaar, Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: A study of two cases, Journal of Medical Virology, 2008, 80, 8
    Direct Link:
  65. 65
    Sharif B. Missiha, Mario Ostrowski, E. Jenny Heathcote, Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors, Gastroenterology, 2008, 134, 6, 1699

    CrossRef

  66. 66
    Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy, Journal of Medical Virology, 2008, 80, 8
    Direct Link:
  67. 67
    Juliane Halangk, Christoph Sarrazin, Konrad Neumann, Gero Puhl, Tobias Mueller, Gerlinde Teuber, Hartwig Klinker, Holger Hinrichsen, Peter Buggisch, Olfert Landt, Viola Weich, Alexandra Bergk, Bertram Wiedenmann, Peter Neuhaus, Thomas Berg, Heiko Witt, Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection, Journal of Hepatology, 2008, 49, 3, 339

    CrossRef

  68. 68
    Omer Alyan, Fehmi Kacmaz, Ozcan Ozdemir, Bulent Deveci, Ramazan Astan, Aksuyek Savas Celebi, Erdogan Ilkay, Hepatitis C Infection is Associated With Increased Coronary Artery Atherosclerosis Defined by Modified Reardon Severity Score System, Circulation Journal, 2008, 72, 12, 1960

    CrossRef

  69. 69
    Miharu Hirakawa, Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients, Internal Medicine, 2008, 47, 19, 1637

    CrossRef

  70. 70
    Yukiko Miura, Akitaka Shibuya, Shigeru Adachi, Atsuko Takeuchi, Takeshi Tsuchihashi, Takahide Nakazawa, Katsunori Saigenji, Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails, Hepatology Research, 2008, 38, 6
    Direct Link:
  71. 71
    Michael von Wagner, Wolf Peter Hofmann, Gerlinde Teuber, Thomas Berg, Tobias Goeser, Ulrich Spengler, Holger Hinrichsen, Hans Weidenbach, Guido Gerken, Michael Manns, Peter Buggisch, Eva Herrmann, Stefan Zeuzem, Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection, Hepatology, 2008, 48, 5
    Direct Link:
  72. 72
    Donatella Ciuffreda, Denis Comte, Matthias Cavassini, Emiliano Giostra, Leo Bühler, Monika Perruchoud, Markus H. Heim, Manuel Battegay, Daniel Genné, Beat Mulhaupt, Raffaele Malinverni, Carl Oneta, Enos Bernasconi, Martine Monnat, Andreas Cerny, Christian Chuard, Jan Borovicka, Gilles Mentha, Manuel Pascual, Jean-Jacques Gonvers, Giuseppe Pantaleo, Valérie Dutoit, Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication, European Journal of Immunology, 2008, 38, 10
    Direct Link:
  73. 73
    Melissa A. Jim, David G. Perdue, Lisa C. Richardson, David K. Espey, John T. Redd, Howard J. Martin, Sandy L. Kwong, Janet J. Kelly, Jeffrey A. Henderson, Faruque Ahmed, Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999–2004, Cancer, 2008, 113, S5
    Direct Link:
  74. 74
    Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma, Journal of Medical Virology, 2008, 80, 8
    Direct Link:
  75. 75
    Edward J. Gane, The natural history of recurrent hepatitis C and what influences this, Liver Transplantation, 2008, 14, S2
    Direct Link:
  76. You have free access to this content76
    Chiung M. Chen, Young-Hee Yoon, Hsiao-ye Yi, Diane L. Lucas, Alcohol and Hepatitis C Mortality Among Males and Females in the United States: A Life Table Analysis, Alcoholism: Clinical and Experimental Research, 2007, 31, 2
    Direct Link:
  77. 77
    Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis, Hepatology, 2007, 46, 5
    Direct Link:
  78. 78
    Arno Kornberg, Bernadett Küpper, Andrea Tannapfel, Erik Bärthel, Katharina Thrum, Utz Settmacher, Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study, Journal of Gastroenterology and Hepatology, 2007, 22, 12
    Direct Link:
  79. 79
    Frank Tacke, Christian Trautwein, Causes of death in hepatitis B and/or C virus infected–people—lessons for clinical practice, Hepatology, 2007, 45, 4
    Direct Link:
  80. 80
    L. Prasad, V. M. Spicher, M. Zwahlen, M. Rickenbach, B. Helbling, F. Negro, Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS), International Journal of Epidemiology, 2007, 36, 4, 731

    CrossRef

  81. 81
    Goran B.G. Klintmalm, W. Kenneth Washburn, Steven M. Rudich, Thomas G. Heffron, Lewis W. Teperman, Carlos Fasola, Devin E. Eckhoff, George J. Netto, Eliezer Katz, Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study, Liver Transplantation, 2007, 13, 11
    Direct Link:
  82. 82
    Shintaro Takaki, Yoshiiku Kawakami, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Toshio Nakanishi, Mikiya Kitamoto, Takashi Moriya, Kenichi Satoh, Kazuaki Chayama, Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin, Intervirology, 2007, 50, 6, 439

    CrossRef

  83. 83
    Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load, Hepatology Research, 2007, 37, 10
    Direct Link:
  84. 84
    Kenji Ikeda, Hepatocellular carcinogenesis after elimination of hepatitis C virus-RNA by interferon therapy, Kanzo, 2007, 48, 2, 43

    CrossRef

  85. 85
    Hashem B. El–Serag, K. Lenhard Rudolph, Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, Gastroenterology, 2007, 132, 7, 2557

    CrossRef

  86. 86
    Yuki Kita, Eishiro Mizukoshi, Toshinari Takamura, Masaru Sakurai, Yoshiko Takata, Kuniaki Arai, Tatsuya Yamashita, Yasunari Nakamoto, Shuichi Kaneko, Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus, Metabolism, 2007, 56, 12, 1682

    CrossRef

  87. 87
    Tomoyoshi Ohno, Noboru Hirashima, Etsuro Orito, Izumi Hasegawa, Kei Fujiwara, Kiyoaki Itoh, Atsushi Ozasa, Noboru Shinkai, Yasuhito Tanaka, Takanobu Kato, Ryuzo Ueda, Kenji Sakakibara, Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma, Hepatology Research, 2007, 37, 4
    Direct Link:
  88. 88
    Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Chiemi Noguchi, Shoichi Takahashi, Eiji Iwao, Yoshifumi Fujimoto, Hiromi Abe, Toshiro Maekawa, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Akihito Sakai, Yoshio Sakai, Masao Honda, Shuichi Kaneko, Takaji Wakita, Kazuaki Chayama, Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon, FEBS Letters, 2007, 581, 10, 1983

    CrossRef

  89. 89
    Scott Seronello, Muhammad Y. Sheikh, Jinah Choi, Redox regulation of hepatitis C in nonalcoholic and alcoholic liver, Free Radical Biology and Medicine, 2007, 43, 6, 869

    CrossRef

  90. 90
    Morris Sherman, Screening for hepatocellular carcinoma, Hepatology Research, 2007, 37,
    Direct Link:
  91. 91
    M. Masarone, V. La Mura, S. Bruno, G. B. Gaeta, R. Vecchione, F. Carrino, F. Moschella, R. Torella, M. Persico, Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease, Journal of Viral Hepatitis, 2007, 14, 10
    Direct Link:
  92. 92
    Morris Sherman, Surveillance for Hepatocellular Carcinoma and Early Diagnosis, Clinics in Liver Disease, 2007, 11, 4, 817

    CrossRef

  93. 93
    Carlos Romero Marrero, Jorge A. Marrero, Viral Hepatitis and Hepatocellular Carcinoma, Archives of Medical Research, 2007, 38, 6, 612

    CrossRef

  94. 94
    Chao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, Jing-Houng Wang, Chien-Hung Chen, Tsung-Hui Hu, Kwong-Ming Kee, Kuo-Chin Chang, Po-Lin Tseng, Yi-Hao Yen, Chi-Sin Changchien, Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response, Liver International, 2006, 26, 9
    Direct Link:
  95. 95
    Kenji Ikeda, Yasuji Arase, Satoshi Saitoh, Masahiro Kobayashi, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center, Intervirology, 2006, 49, 1-2, 82

    CrossRef

  96. 96
    Janaki Amin, Matthew G Law, Mark Bartlett, John M Kaldor, Gregory J Dore, Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study, The Lancet, 2006, 368, 9539, 938

    CrossRef

  97. 97
    Morris Sherman, Chronic Hepatitis C and Screening for Hepatocellular Carcinoma, Clinics in Liver Disease, 2006, 10, 4, 735

    CrossRef

  98. 98
    Ming-Yang Lai, Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan, Intervirology, 2006, 49, 1-2, 91

    CrossRef

  99. 99
    G. V. Papatheodoridis, N. Chrysanthos, S. Savvas, V. Sevastianos, G. Kafiri, K. Petraki, E. K. Manesis, Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis, Journal of Viral Hepatitis, 2006, 13, 5
    Direct Link:
  100. 100
    Stefan Zeuzem, Maria Buti, Peter Ferenci, Jan Sperl, Yves Horsmans, Janusz Cianciara, Endre Ibranyi, Ola Weiland, Stephanie Noviello, Clifford Brass, Janice Albrecht, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia, Journal of Hepatology, 2006, 44, 1, 97

    CrossRef

  101. 101
    Kiminori Uka, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection, Journal of Gastroenterology, 2006, 41, 5, 470

    CrossRef

  102. 102
    Marc G. Ghany, Leonard B. Seeff, Efforts to Define the Natural History of Chronic Hepatitis C Continue, Clinical Gastroenterology and Hepatology, 2006, 4, 10, 1190

    CrossRef

  103. 103
    Beat Helbling, Wolfram Jochum, Ivan Stamenic, Marina Knöpfli, Andreas Cerny, J. Borovicka, Jean-Jacques Gonvers, Martin Wilhelmi, Sabine Dinges, Beat Müllhaupt, Alicia Esteban, Beat Meyer-Wyss, Eberhard L. Renner, HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon α-2a and ribavirin, Journal of Viral Hepatitis, 2006, 13, 11
    Direct Link:
  104. 104
    John B Wong, Hepatitis C, PharmacoEconomics, 2006, 24, 7, 661

    CrossRef

  105. 105
    F. Monica, F. Lirussi, I. Pregun, F. Vasile, L. Fabris, L. Okolicsanyi, Hepatitis C virus infection in a resident elderly population: A 10-year follow-up study, Digestive and Liver Disease, 2006, 38, 5, 336

    CrossRef

  106. 106
    Maria Varela, William Sanchez, Jordi Bruix, Gregory J. Gores, Hepatocellular carcinoma in the setting of liver transplantation, Liver Transplantation, 2006, 12, 7
    Direct Link:
  107. 107
    M.A. Serra, Historia natural de la infección por virus C, Gastroenterología y Hepatología, 2006, 29, 101

    CrossRef

  108. 108
    Michiko Jo, Norio Nakamura, Nobuko Kakiuchi, Katsuko Komatsu, Ming-hua Qui, Kumiko Shimotohno, Kunitada Shimotohno, Masao Hattori, Inhibitory effect of Yunnan traditional medicines on hepatitis C viral polymerase, Journal of Natural Medicines, 2006, 60, 3, 217

    CrossRef

  109. 109
    C.-H. Hung, C.-M. Lee, S.-N. Lu, J.-H. Wang, T.-H. Hu, H.-D. Tung, C.-H. Chen, W.-J. Chen, C.-S. Changchien, Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Journal of Viral Hepatitis, 2006, 13, 6
    Direct Link:
  110. 110
    Masahiro Kobayashi, Kenji Ikeda, Tetsuya Hosaka, Hitomi Sezaki, Takashi Someya, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Yuzo Miyakawa, Hiromitsu Kumada, Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections, Journal of Medical Virology, 2006, 78, 4
    Direct Link:
  111. 111
    A. DE GOTTARDI, V. PAZIENZA, P. PUGNALE, F. BRUTTIN, L. RUBBIA-BRANDT, C. E. JUGE-AUBRY, C. A. MEIER, A. HADENGUE, F. NEGRO, Peroxisome proliferator-activated receptor-α and -γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection, Alimentary Pharmacology & Therapeutics, 2006, 23, 1
    Direct Link:
  112. 112
    Maribel Rodr??guez-Torres, Carlos F. R??os-Bedoya, Jos?? Rodr??guez-Orengo, Alberto Fern??ndez-Carbia, Acisclo M. Marxuach-Cu??tara, Abimael L??pez-Torres, Rosa Salgado-Mercado, Norbert Br??u, Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender, Journal of Clinical Gastroenterology, 2006, 40, 4, 358

    CrossRef

  113. 113
    Gioacchino Leandro, Alessandra Mangia, Jason Hui, Paolo Fabris, Laura Rubbia–Brandt, Guido Colloredo, Luigi E. Adinolfi, Tarik Asselah, Julie R. Jonsson, Antonina Smedile, Norah Terrault, Valerio Pazienza, Maria Teresa Giordani, Emiliano Giostra, Aurelio Sonzogni, Giuseppe Ruggiero, Patrick Marcellin, Elizabeth E. Powell, Jacob George, Francesco Negro, Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data, Gastroenterology, 2006, 130, 6, 1636

    CrossRef

  114. 114
    U. MIHM, E. HERRMANN, C. SARRAZIN, S. ZEUZEM, Review article: predicting response in hepatitis C virus therapy, Alimentary Pharmacology & Therapeutics, 2006, 23, 8
    Direct Link:
  115. 115
    Masatoshi Akamatsu, Haruhiko Yoshida, Shuichiro Shiina, Takuma Teratani, Shuntaro Obi, Ryousuke Tateishi, Norio Mine, Yuji Kondo, Takao Kawabe, Masao Omata, Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma, Liver International, 2006, 26, 5
    Direct Link:
  116. 116
    Angelo Sangiovanni, Gian Maria Prati, Pierangelo Fasani, Guido Ronchi, Raffaella Romeo, Matteo Manini, Ersilio Del Ninno, Alberto Morabito, Massimo Colombo, The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatology, 2006, 43, 6
    Direct Link:
  117. 117
    M. Mazen Jamal, Zainab Saadi, Timothy R. Morgan, Alcohol and Hepatitis C, Digestive Diseases, 2005, 23, 3-4, 285

    CrossRef

  118. 118
    Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Sachiyo Watahiki, Junko Sato, Marie Matsuda, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy, Intervirology, 2005, 48, 6, 372

    CrossRef

  119. 119
    Nobuhiko Hiraga, Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hitomi Sezaki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Marie Matsuda, Sachiko Watabiki, Junko Satoh, Hiromitsu Kumada, Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up, Journal of Medical Virology, 2005, 75, 2
    Direct Link:
  120. 120
    Yasuhiro Kuramitsu, Kazuyuki Nakamura, Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma, Expert Review of Proteomics, 2005, 2, 4, 589

    CrossRef

  121. 121
    Katherine A. McGlynn, W.Thomas London, Epidemiology and natural history of hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 2005, 19, 1, 3

    CrossRef

  122. 122
    V. Sypsa, G. Touloumi, G. V. Papatheodoridis, N. C. Tassopoulos, I. Ketikoglou, I. Vafiadis, G. Hatzis, D. Tsantoulas, E. Akriviadis, S. Koutsounas, A. Hatzakis, Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments, Journal of Viral Hepatitis, 2005, 12, 5
    Direct Link:
  123. 123
    S. Keating, S. Coughlan, J. Connell, B. Sweeney, E. Keenan, Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area, Irish Journal of Medical Science, 2005, 174, 1, 37

    CrossRef

  124. 124
    Lisa I Backus, Derek Boothroyd, Lawrence R Deyton, HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations, AIDS, 2005, 19, Suppl 3, S13

    CrossRef

  125. 125
    Hiroshi Kamitsukasa, Hideharu Harada, Hideo Tanaka, Michiyasu Yagura, Hajime Tokita, Akira Ohbayashi, Late liver-related mortality from complications of transfusion-acquired hepatitis C, Hepatology, 2005, 41, 4
    Direct Link:
  126. 126
    Jordi Bruix, Morris Sherman, Management of hepatocellular carcinoma, Hepatology, 2005, 42, 5
    Direct Link:
  127. 127
    Takuichi Oikawa, Hidenori Ojima, Susumu Yamasaki, Tadatoshi Takayama, Setsuo Hirohashi, Michiie Sakamoto, Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules, Journal of Hepatology, 2005, 42, 2, 225

    CrossRef

  128. 128
    David L. Thomas, Leonard B. Seeff, Natural History of Hepatitis C, Clinics in Liver Disease, 2005, 9, 3, 383

    CrossRef

  129. 129
    Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem, Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C, Gastroenterology, 2005, 129, 2, 522

    CrossRef

  130. 130
    Jos?? R. Foruny, Javier Bl??zquez, Ana Moreno, Rafael B??rcena, Luis Gil-Grande, Carmen Quereda, Mar??a J. P??rez-El??as, Javier Moreno, Juan S??nchez, Alfonso Muriel, Miguel A. Rodriguez-Sagrado, Santiago Moreno, Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization, European Journal of Gastroenterology & Hepatology, 2005, 17, 11, 1157

    CrossRef

  131. 131
    Morris Sherman, Screening for hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 2005, 19, 1, 101

    CrossRef

  132. 132
    Anne M. Larson, The epidemiology of hepatocellular carcinoma in hcv, Current Hepatitis Reports, 2005, 4, 4, 145

    CrossRef

  133. 133
    Calogero Cammà, Anna Licata, Giuseppe Cabibbo, Federica Latteri, Antonio Craxì, Treatment of hepatitis C: critical appraisal of the evidence, Expert Opinion on Pharmacotherapy, 2005, 6, 3, 399

    CrossRef

  134. 134
    Paolo Fabris, Annarosa Floreani, Antonio Carlotto, Maria Teresa Giordani, Vincenzo Baldo, Clara Stecca, Lorella Marchioro, Andrea Tramarin, Tosca Bertin, Francesco Negro, Fausto de Lalla, Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C, Journal of Hepatology, 2004, 41, 4, 644

    CrossRef

  135. 135
    Robert J Fontana, Gregory T Everson, Sony Tuteja, Hugo E Vargas, Mitchell L Shiffman, Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis, Clinical Gastroenterology and Hepatology, 2004, 2, 3, 183

    CrossRef

  136. 136
    S. D. Sullivan, D. M. Jensen, D. E. Bernstein, T. I. Hassanein, G. R. Foster, S. S. Lee, H. Cheinquer, A. Craxi, Graham Cooksley, W. Klaskala, K. Pettit, K. K. Patel, J. Green, Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C, The American Journal of Gastroenterology, 2004, 99, 8, 1490

    CrossRef

  137. 137
    Susan M. McKiernan, Richard Hagan, Michael Curry, George S. A. McDonald, Alan Kelly, Niamh Nolan, Anne Walsh, John Hegarty, Emer Lawlor, Dermot Kelleher, Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source, Hepatology, 2004, 40, 1
    Direct Link:
  138. 138
    Dana L. Bruden, Brian J. McMahon, Thomas W. Hennessy, Carol J. Christensen, Chriss E. Homan, James L. Williams, Daniel G. Sullivan, David R. Gretch, Henry H. Cagle, Lisa R. Bulkow, Estimating the Date of Hepatitis C Virus Infection from Patient Interviews and Antibody Tests on Stored Sera, The American Journal of Gastroenterology, 2004, 99, 8, 1517

    CrossRef

  139. 139
    Giovanna Fattovich, Tommaso Stroffolini, Irene Zagni, Francesco Donato, Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, 2004, 127, 5, S35

    CrossRef

  140. 140
    Archana Sud, Jason M. Hui, Geoffrey C. Farrell, Priyanka Bandara, James G. Kench, Carolyn Fung, Rita Lin, Dev Samarasinghe, Christopher Liddle, Geoffrey W. McCaughan, Jacob George, Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index, Hepatology, 2004, 39, 5
    Direct Link:
  141. 141
    A. Kasahara, H. Tanaka, T. Okanoue, Y. Imai, H. Tsubouchi, K. Yoshioka, S. Kawata, E. Tanaka, K. Hino, K. Hayashi, S. Tamura, Y. Itoh, K. Kiyosawa, S. Kakumu, K. Okita, N. Hayashi, Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death, Journal of Viral Hepatitis, 2004, 11, 2
    Direct Link:
  142. 142
    G. Campisi, O. Di Fede, A. Craxı̀, R. Di Stefano, V. Margiotta, Oral lichen planus, hepatitis C virus, and HIV: No association in a cohort study from an area of high hepatitis C virus endemicity, Journal of the American Academy of Dermatology, 2004, 51, 3, 364

    CrossRef

  143. 143
    Morris Sherman, Pathogenesis and screening for hepatocellular carcinoma, Clinics in Liver Disease, 2004, 8, 2, 419

    CrossRef

  144. 144
    T. Jake Liang, Theo Heller, Pathogenesis of hepatitis C—associated hepatocellular carcinoma, Gastroenterology, 2004, 127, 5, S62

    CrossRef

  145. 145
    E. Jenny Heathcote, Prevention of hepatitis C virus–related hepatocellular carcinoma, Gastroenterology, 2004, 127, 5, S294

    CrossRef

  146. 146
    Hideo Tanaka, Hideaki Tsukuma, Hajime Yamano, Akira Oshima, Hirotoshi Shibata, Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus, International Journal of Cancer, 2004, 112, 6
    Direct Link:
  147. 147
    Yasuhiro Kuramitsu, Kazuyuki Nakamura, Proteomics for hepatocellular carcinoma, SEIBUTSU BUTSURI KAGAKU, 2004, 48, 3, 93

    CrossRef

  148. 148
    Stefan Mauss, William Valenti, Jean DePamphilis, Frank Duff, Lisa Cupelli, Sharon Passe, Jonathan Solsky, Francesca J Torriani, Douglas Dieterich, Dominique Larrey, Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy, AIDS, 2004, 18, 13, 21

    CrossRef

  149. 149
    Morris Sherman, Yuji Takayama, Screening and treatment for hepatocellular carcinoma, Gastroenterology Clinics of North America, 2004, 33, 3, 671

    CrossRef

  150. 150
    W. Ray Kim, John J. Poterucha, Joanne T. Benson, Terry M. Therneau, The impact of competing risks on the observed rate of chronic hepatitis C progression, Gastroenterology, 2004, 127, 3, 749

    CrossRef

  151. 151
    Scott K. Fung, Anna S.F. Lok, Viral hepatitis in 2003, Current Opinion in Gastroenterology, 2004, 20, 3, 241

    CrossRef

  152. 152
    T. E. S. Delahooke, What is the nature of the problem?, Journal of Viral Hepatitis, 2004, 11,
    Direct Link:
  153. 153
    Gabriel Perlemuter, Philippe Lettéron, Françoise Carnot, Flora Zavala, Dominique Pessayre, Bertrand Nalpas, Christian Bréchot, Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model, Journal of Hepatology, 2003, 39, 6, 1020

    CrossRef

  154. 154
    Norio Akuta, Fumitaka Suzuki, Akihito Tsubota, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy, Journal of Medical Virology, 2003, 69, 3
    Direct Link:
  155. 155
    Paloma Jara, Massimo Resti, Loreto Hierro, Raffaella Giacchino, Cristiana Barbera, Lucia Zancan, Carlo Crivellaro, Etienne Sokal, Chiara Azzari, Maria Guido, Flavia Bortolotti, Chronic Hepatitis C Virus Infection in Childhood: Clinical Patterns and Evolution in 224 White Children, Clinical Infectious Diseases, 2003, 36, 3, 275

    CrossRef

  156. 156
    R. Pérez, M. Jiménez, J. Crespo, M. Diago, J. Enríquez, P. Vaquero, R. Solá, J. L. Olcoz, M. Romero, J. Salmerón, Mª I. Blanco, Mª Oña, S. Melón, L. Rodrigo, Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C, Journal of Viral Hepatitis, 2003, 10, 6
    Direct Link:
  157. 157
    Arshad K Butt, Ayyaz A Khan, Saman Y Khan, Sharea Ijaz, Dentistry as a possible route of hepatitis C transmission in Pakistan, International Dental Journal, 2003, 53, 3
    Direct Link:
  158. 158
    Renuka Bhattacharya, Margaret C. Shuhart, Hepatitis C and Alcohol, Journal of Clinical Gastroenterology, 2003, 36, 3, 242

    CrossRef

  159. 159
    Robert A. Yoho, Leonard L. Cruz, Reza Mazaheri, Andrea T. Cruz, Hepatitis C: A Review, Plastic and Reconstructive Surgery, 2003, 112, 2, 597

    CrossRef

  160. 160
    M.Mazen Jamal, Timothy R Morgan, Liver disease in alcohol and hepatitis C, Best Practice & Research Clinical Gastroenterology, 2003, 17, 4, 649

    CrossRef

  161. 161
    Kenneth D. Phillips, Robyn Brewer, Pathophysiology of Hepatitis C and HIV Coinfection, Journal of the Association of Nurses in AIDS care, 2003, 14, 5, 27S

    CrossRef

  162. 162
    John F Perry, Simone I Strasser, Jacob George, Geoffrey C Farrell, Geoffrey W McCaughan, Pharmacotherapy of hepatocellular carcinoma, Expert Opinion on Pharmacotherapy, 2003, 4, 12, 2175

    CrossRef

  163. 163
    Gerlinde Teuber, M Pascu, T Berg, M Lafrenz, J Pausch, F Kullmann, G Ramadori, R Arnold, H Weidenbach, E Musch, U Junge, K.H Wiedmann, E Herrmann, M Zankel, S Zeuzem, Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C, Journal of Hepatology, 2003, 39, 4, 606

    CrossRef

  164. 164
    David E Kaplan, K.Rajender Reddy, Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes, Clinics in Liver Disease, 2003, 7, 3, 683

    CrossRef

  165. 165
    Roberta Nardacci, Oreste Lo Iacono, Fabiola Ciccosanti, Laura Falasca, Maria Addesso, Alessandra Amendola, Giorgio Antonucci, Antonio Craxì, Gian Maria Fimia, Valentina Iadevaia, Gerry Melino, Luigi Ruco, Guido Tocci, Giuseppe Ippolito, Mauro Piacentini, Transglutaminase Type II Plays a Protective Role in Hepatic Injury, The American Journal of Pathology, 2003, 162, 4, 1293

    CrossRef

  166. 166
    M. Tabone, L. Sidoli, C. Laudi, S. Pellegrino, G. Rocca, P. Della Monica, M. Fracchia, G. Galatola, G. C. Molinaro, S. Aricò, A. Pera, Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy, Journal of Viral Hepatitis, 2002, 9, 4
    Direct Link:
  167. 167
    Kathleen Iosue, Chronic Hepatitis C: Latest Treatment Options, The Nurse Practitioner, 2002, 27, 4, 32

    CrossRef

  168. 168
    Sandro Vento, Francesca Cainelli, Does hepatitis C virus cause severe liver disease only in people who drink alcohol?, The Lancet Infectious Diseases, 2002, 2, 5, 303

    CrossRef

  169. 169
    Shuichi Okada, Katsuaki Tanaka, Tosiya Sato, Hideki Ueno, Satoru Saito, Takuji Okusaka, Keiko Sato, Seiichiro Yamamoto, Tadao Kakizoe, Dose-response Trial of Lactoferrin in Patients with Chronic Hepatitis C, Cancer Science, 2002, 93, 9
    Direct Link:
  170. 170
    Norio Akuta, Fumitaka Suzuki, Akihito Tsubota, Yoshiyuki Suzuki, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors, Journal of Hepatology, 2002, 37, 6, 831

    CrossRef

  171. 171
    Hashem B. El-Serag, Hepatocellular carcinoma and hepatitis C in the United States, Hepatology, 2002, 36, S1
    Direct Link:
  172. 172
    Christoph Sarrazin, Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance, Journal of Clinical Virology, 2002, 25, 23

    CrossRef

  173. 173
    Hisayuki Hamada, Hiroshi Yatsuhashi, Koji Yano, Manabu Daikoku, Kokichi Arisawa, Osami Inoue, Michiaki Koga, Keisuke Nakata, Katsumi Eguchi, Michitami Yano, Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C, Cancer, 2002, 95, 2
    Direct Link:
  174. 174
    Timothy M. McCashland, INTERFERON: THE FOUNTAIN OF YOUTH?, Evidence-Based Gastroenterology, 2002, 3, 4, 126

    CrossRef

  175. 175
    Gregory J Dore, Anthony J Freeman, Matthew Law, JohnM Kaldor, Is severe liver disease a common outcome for people with chronic hepatitisC?, Journal of Gastroenterology and Hepatology, 2002, 17, 4
    Direct Link:
  176. 176
    Kazuaki Chayama, Management of chronic hepatitis C and prevention of hepatocellular carcinoma, Journal of Gastroenterology, 2002, 37, S13, 69

    CrossRef

  177. 177
    J. Westin, L. M. Lagging, F. Spak, N. Aires, E. Svensson, M. Lindh, A. P. Dhillon, G. Norkrans, R. Wejstål, Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection, Journal of Viral Hepatitis, 2002, 9, 3
    Direct Link:
  178. 178
    Leonard B. Seeff, Natural history of chronic hepatitis C, Hepatology, 2002, 36, S1
    Direct Link:
  179. 179
    Markus Sagmeister, Eberhard L. Renner, Beat Mullhaupt, John B. Wong, Simulation of hepatitis C based on a mandatory reporting system, European Journal of Gastroenterology & Hepatology, 2002, 14, 1, 25

    CrossRef

  180. 180
    Robert B. Perni, Ann D. Kwong, Progress in Medicinal Chemistry Volume 39, 2002,

    CrossRef

  181. 181
    Masataka Okuno, Soichi Kojima, Hisataka Moriwaki, Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives, Journal of Gastroenterology and Hepatology, 2001, 16, 12
    Direct Link:
  182. 182
    Kazuaki Chayama, Fumitaka Suzuki, Akihito Tsubota, Norio Akuta, Takashi Someya, Masahiro Kobayashi, Yasuji Arase, Satoshi Saitoh, Yoshiyuki Suzuki, Kenji Ikeda, Hiromitsu Kumada, Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype, Journal of Virological Methods, 2001, 95, 1-2, 33

    CrossRef

  183. 183
    Alexander C Haushofer, Camel Kopty, Rene Hauer, Harald Brunner, Walter-Michael Halbmayer, HCV genotypes and age distribution in patients of Vienna and surrounding areas, Journal of Clinical Virology, 2001, 20, 1-2, 41

    CrossRef

  184. 184
    E. Herrero Martínez, Hepatitis B and hepatitis C co-infection in patients with HIV, Reviews in Medical Virology, 2001, 11, 4
    Direct Link:
  185. 185
    Francis Yao, Norah Terrault, Hepatitis C and hepatocellular carcinoma, Current Treatment Options in Oncology, 2001, 2, 6, 473

    CrossRef

  186. 186
    Georg M. Lauer, Bruce D. Walker, Hepatitis C Virus Infection, New England Journal of Medicine, 2001, 345, 1, 41

    CrossRef

  187. 187
    Herbert L. Bonkovsky, Savant Mehta, Hepatitis C: A review and update, Journal of the American Academy of Dermatology, 2001, 44, 2, 159

    CrossRef

  188. 188
    Herbert L. Bonkovsky, Savant Mehta, Hepatitis C: A review and update, Disease-a-Month, 2001, 47, 12, 610

    CrossRef

  189. 189
    V. Di Marco, A. Vaccaro, D. Ferraro, G. Alaimo, V. Rodolico, P. Parisi, S. Peralta, R. Di Stefano, P. L. Almasio, A. Craxì, High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2001, 15, 7
    Direct Link:
  190. 190
    Ezequiel Balmori Melian, Greg L. Plosker, Interferon Alfacon-1, Drugs, 2001, 61, 11, 1661

    CrossRef

  191. 191
    Isabelle Beurton, Marie-Anne Bertrand, Solange Bresson-Hadni, Armelle Parquet-Gernez, Jenny Goudemand, Jean-Claude Paris, Paul Cales, Marie-Elisabeth Briquel, Pierre Gaucher, Marie-Luce Cortey, Christian Trepo, Jean-Philippe Miguet, Jean-Yves Cahn, Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients, European Journal of Gastroenterology & Hepatology, 2001, 13, 7, 859

    CrossRef

  192. 192
    Katherine A. McGlynn, Lilian Tsao, Ann W. Hsing, Susan S. Devesa, Joseph F. Fraumeni, International trends and patterns of primary liver cancer, International Journal of Cancer, 2001, 94, 2
    Direct Link:
  193. 193
    Isao Nakano, Yoshihide Fukuda, Yoshiaki Katano, Hidenori Toyoda, Kazuhiko Hayashi, Takashi Kumada, Satoshi Nakano, Japan-specific subtype of hepatitis C virus genotype 1b, J subtype, has relatively low pathogenicity, Journal of Medical Virology, 2001, 65, 1
    Direct Link:
  194. 194
    Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Akihito Tsubota, Yasuji Arase, Naoya Murashima, Kazuaki Chayama, Hiromitsu Kumada, Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study, Journal of Gastroenterology and Hepatology, 2001, 16, 4
    Direct Link:
  195. 195
    Yasushi Shiratori, Haruhiko Yoshida, Masao Omata, Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention, Expert Review of Anticancer Therapy, 2001, 1, 2, 277

    CrossRef

  196. 196
    Alajos Pár, László Telegdy, Lajos Dalmi, Eva Müller, Therapy for chronic hepatitis C, Journal of Physiology-Paris, 2001, 95, 1-6, 399

    CrossRef

  197. 197
    Hirotsugu Ikawa, Yoshitake Hayashi, Toshiaki Ninomiya, Yoshihiko Yano, Miyuki Nakaji, Hidenobu Nagano, Yasushi Seo, Yoshiko Kumon, Seitetsu Yoon, Masato Kasuga, Hiroshi Itoh, Chiho Ohbayashi, Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon, Human Pathology, 2001, 32, 9, 910

    CrossRef

  198. 198
    Arturo Pereira, Cristina Sanz, A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols, Transfusion, 2000, 40, 10
    Direct Link:
  199. 199
    Vito Di Marco, Piero Almasio, Alessandra Vaccaro, Donatella Ferraro, Pietro Parisi, Maria Gabriella Cataldo, Rosa Di Stefano, Antonio Craxì, Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months, Journal of Hepatology, 2000, 33, 3, 456

    CrossRef

  200. 200
    John B Wong, Gary L Davis, Stephen G Pauker, Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C, The American Journal of Medicine, 2000, 108, 5, 366

    CrossRef

  201. 201
    John B. Wong, Thierry Poynard, Mei-Hsiu Ling, Janice K. Albrecht, Stephen G. Pauker, Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c, The American Journal of Gastroenterology, 2000, 95, 6, 1524

    CrossRef

  202. 202
    W. Ray Kim, John J. Poterucha, Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C, Hepatology, 2000, 31, 3
    Direct Link:
  203. 203
    Hideo Tanaka, Hideaki Tsukuma, Akinori Kasahara, Norio Hayashi, Harumasa Yoshihara, Manabu Masuzawa, Tsutomu Kanda, Tohoru Kashiwagi, Atsuo Inoue, Michio Kato, Akira Oshima, Yoko Kinoshita, Takenobu Kamada, Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients, International Journal of Cancer, 2000, 87, 5
    Direct Link:
  204. 204
    G.W. McCaughan, A. Zekry, Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection, Transplant Infectious Disease, 2000, 2, 4
    Direct Link:
  205. 205
    James J. Farrell, Lawrence S. Friedman, GASTROINTESTINAL BLEEDING IN OLDER PEOPLE, Gastroenterology Clinics of North America, 2000, 29, 1, 1

    CrossRef

  206. 206
    Catherine Petruff Cheney, Sanjiv Chopra, Camilla Graham, HEPATITIS C, Infectious Disease Clinics of North America, 2000, 14, 3, 633

    CrossRef

  207. 207
    John T. Edwards, Graeme A. Macdonald, Hepatocellular carcinoma, Current Opinion in Gastroenterology, 2000, 16, 3, 275

    CrossRef

  208. 208
    Orla M. Crosbie, Graeme J.M. Alexander, Liver transplantation for hepatitis C virus related cirrhosis, Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 307

    CrossRef

  209. 209
    Masao Omata, Yasushi Shiratori, Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  210. 210
    Hiroshi Yatsuhashi, Michitami Yano, Natural history of chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  211. 211
    Deepak Amarapurkar, Natural history of hepatitis C virus infection, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  212. 212
    Thomas F. Imperiale, Areen T. Said, Oscar W. Cummings, Lawrence J. Born, Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C, The American Journal of Gastroenterology, 2000, 95, 9, 2328

    CrossRef

  213. 213
    Yasushi Shiratori, Masao Omata, Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  214. 214
    Mahbub H. Khan, Geoffrey C. Farrell, Karen Byth, Rita Lin, Martin Weltman, Jacob George, Dev Samarasinghe, James Kench, Songal Kaba, Evelyn Crewe, Chris Liddle, Which patients with hepatitis C develop liver complications?, Hepatology, 2000, 31, 2
    Direct Link:
  215. 215
    Leonard B. Seeff, Why is there such difficulty in defining the natural history of hepatitis C?, Transfusion, 2000, 40, 10
    Direct Link:
  216. 216
    John B Wong, Cost-effectiveness of treatments for chronic hepatitis C, The American Journal of Medicine, 1999, 107, 6, 74

    CrossRef

  217. 217
    Antonio Craxï, Calogero Cammà, Marco Giunta, Definition of response to antiviral therapy in chronic hepatitis C, Journal of Hepatology, 1999, 31, 160

    CrossRef

  218. 218
    P.-A. Mårdh, M. Shoubnikova, M. Genç, S. Chaplinkas, V. Unzeitig, Health care of female commercial sex workers, The European Journal of Contraception and Reproductive Health Care, 1999, 4, 3, 165

    CrossRef

  219. 219
    Arie Regev, Lennox J. Jeffers, Hepatitis C and Alcohol, Alcoholism: Clinical and Experimental Research, 1999, 23, 9
    Direct Link:
  220. 220
    Maureen M. Jonas, Hepatitis C Infection in Children, New England Journal of Medicine, 1999, 341, 12, 912

    CrossRef

  221. 221
    Geoffrey C Farrell, Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws?, Journal of Gastroenterology and Hepatology, 1999, 14, 9
    Direct Link:
  222. 222
    Alfredo Alberti, Liliana Chemello, Luisa Benvegnù, Natural history of hepatitis C, Journal of Hepatology, 1999, 31, 17

    CrossRef

  223. 223
    Morris Sherman, Screening for hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 1999, 13, 4, 623

    CrossRef

  224. 224
    The Care of Patients Undergoing Hemodialysis, New England Journal of Medicine, 1999, 340, 9, 735

    CrossRef

  225. 225
    Nedim Ince, Jack R. Wands, The Increasing Incidence of Hepatocellular Carcinoma, New England Journal of Medicine, 1999, 340, 10, 798

    CrossRef

  226. 226
    Ke-Qin Hu, Myron J. Tong, The long-term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states, Hepatology, 1999, 29, 4
    Direct Link:
  227. 227
    Leonard B. Seeff, The natural history of hepatitis C—A quandary, Hepatology, 1998, 28, 6
    Direct Link:
  228. 228
    Diarmuid S. Manning, Nezam H. Afdhal, Antivirals in Cirrhosis and Portal Hypertension,
    Direct Link:
  229. 229
    Morris Sherman, Primary Malignant Neoplasms of the Liver,
    Direct Link:
  230. 230
    Lise Lotte Gluud, Kim Krogsgaard, Christian Gluud, Ribavirin with or without alpha interferon for chronic hepatitis C, The Cochrane Library,
    Direct Link:
Get PDF (110K)